COMP <GO>
ARQT vs UNH // FREE CASH FLOW YIELD
Arcutis Biotherapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ARQT 5
— UNH 9
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $32.07 (+0.31%) • MKT CAP: $4.02B
fcf-yield
-0.16%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | 88.57% | +1.63 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | 11.47% | -14.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -0.16% | 6.48% | -6.64 | UNH | /fcf-yield <GO> |
| Operating Margin | -3.30% | 4.82% | -8.12 | UNH | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 3.14% | -7.44 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 6.46% | +84.84 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 3.12 | +4.66 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.3 | 56.0 | +10.29 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.33 | +0.67 | ARQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 17.1x | +6.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $364.66B | -$360.64B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | UNH REV | ARQT GROSS % | UNH GROSS % | ARQT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $447.57B | 90.2% | 88.7% | -$6.3M | $16.07B |
| FY 2024 | $196.5M | $400.28B | 90.3% | 88.3% | -$112.3M | $20.70B |
| FY 2023 | $59.6M | $371.62B | 44.0% | 89.6% | -$249.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
UNH // BETA 0.33